TAPINAROF - Generic Drug Details

What are the generic drug sources for tapinarof and what is the scope of patent protection?

Tapinarof is the generic ingredient in one branded drug marketed by Organon Llc and is included in one NDA. There are eleven patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Tapinarof has eighty-one patent family members in thirty-nine countries.

One supplier is listed for this compound.

Summary for TAPINAROF

International Patents:	81
US Patents:	11
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	60
Clinical Trials:	18
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for TAPINAROF
What excipients (inactive ingredients) are in TAPINAROF?	TAPINAROF excipients list
DailyMed Link:	TAPINAROF at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for TAPINAROF

Dosage:

CREAM;TOPICAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for TAPINAROF

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of California, San Francisco	PHASE4
Organon and Co	PHASE3
Northwestern University	EARLY_PHASE1

See all TAPINAROF clinical trials

Pharmacology for TAPINAROF

Drug Class	Aryl Hydrocarbon Receptor Agonist
Mechanism of Action	Aryl Hydrocarbon Receptor Agonists

Anatomical Therapeutic Chemical (ATC) Classes for TAPINAROF

D05AX	Other antipsoriatics for topical use
D05A	ANTIPSORIATICS FOR TOPICAL USE
D05	ANTIPSORIATICS
D	Dermatologicals

US Patents and Regulatory Information for TAPINAROF

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Organon Llc	VTAMA	tapinarof	CREAM;TOPICAL	215272-001	May 23, 2022		RX	Yes	Yes				Y
Organon Llc	VTAMA	tapinarof	CREAM;TOPICAL	215272-001	May 23, 2022		RX	Yes	Yes
Organon Llc	VTAMA	tapinarof	CREAM;TOPICAL	215272-001	May 23, 2022		RX	Yes	Yes			Y
Organon Llc	VTAMA	tapinarof	CREAM;TOPICAL	215272-001	May 23, 2022		RX	Yes	Yes			Y
Organon Llc	VTAMA	tapinarof	CREAM;TOPICAL	215272-001	May 23, 2022		RX	Yes	Yes			Y	Y
Organon Llc	VTAMA	tapinarof	CREAM;TOPICAL	215272-001	May 23, 2022		RX	Yes	Yes			Y
Organon Llc	VTAMA	tapinarof	CREAM;TOPICAL	215272-001	May 23, 2022		RX	Yes	Yes

International Patents for TAPINAROF

Country	Patent Number	Title	Estimated Expiration
Japan	2021502333	タピナロフを調製するためのプロセス
European Patent Office	3297605
Japan	6863904
Taiwan	201705940	Topical pharmaceutical compositions
Mexico	377629	COMPOSICIONES FARMACÉUTICAS TÓPICAS. (TOPICAL PHARMACEUTICAL COMPOSITIONS)
Mexico	2020012595	COMPOSICIONES FARMACEUTICAS TOPICAS. (TOPICAL PHARMACEUTICAL COMPOSITIONS.)
Denmark	3297605

TAPINAROF Market Analysis and Financial Projection

Last updated: February 14, 2026

What Are the Market Dynamics for Tapinarof?

Tapinarof is an orally administered aryl hydrocarbon receptor modulator approved in the US as a topical anti-inflammatory treatment for plaque psoriasis and atopic dermatitis. It is under investigation for multiple dermatological and inflammatory conditions, including vitiligo and hidradenitis suppurativa.

Market Size and Segments

The global dermatology market was valued at $23.4 billion in 2022, expected to grow at a CAGR of 7.2% through 2030, driven by increasing prevalence of chronic skin conditions and advancements in topical and systemic therapies[1].

Within this, the psoriasis segment accounts for nearly 60% of the dermatology market, valued at $14 billion in 2022. Atopic dermatitis contributes approximately 20%, with the remaining 20% shared among other indications.

Key Factors Driving Demand

• Unmet Medical Need: Moderate to severe psoriasis and atopic dermatitis have limited effective long-term treatments.
• Safety Profile: Tapinarof’s favorable safety, compared to systemic immunosuppressants, increases its chance of widespread adoption.
• Market Penetration: Early post-approval launches in the US and Europe are expanding, with future approvals anticipated globally.
• Competitive Landscape: Existing therapies include biologics, systemic agents, and corticosteroids. The emergence of topical agents with novel mechanisms offers differentiation.

Competitive Position

Tapinarof is positioned as a first-in-class aryl hydrocarbon receptor modulator. Its differentiating features include a generally mild safety profile and convenient topical administration. It competes with established biologics (e.g., Humira, Cosentyx) and newer topical agents, such as crisaborole and delgocitinib.

What Is the Financial Trajectory of Tapinarof?

Revenue Projections

• Initial Launch (2022-2023): Estimated global sales of $150-200 million, primarily in US markets.
• Mid-Term (2024-2027): Sales could reach $600-800 million with expanded indications and market penetration.
• Long-term (2028+): Potential surpassing $1 billion in global sales subject to approval and market acceptance.

Revenue Drivers

• Indication Expansion: Trials for vitiligo and other inflammatory skin diseases anticipate approval within 3-4 years.
• Pricing Strategy: Topical drugs typically pricing between $5,000–$15,000 annually, with discounts for generics or biosimilars when applicable.
• Market Penetration Rate: Expected to reach 20-30% of eligible patients within 5 years, amid competition and payer coverage.

Cost Considerations

• Regulatory approval costs vary but average $500 million to $800 million per indication, including clinical trials and commercialization expenses[2].
• Manufacturing and distribution costs for topical agents are relatively low compared to biologics, favoring higher margins.

Investment Outlook

• Phase III data and regulatory submissions are pivotal milestones. Under favorable conditions, licensing agreements or partnership deals may boost revenue streams.
• Patent exclusivity extends into 2030s, providing a window for market capture.

What Are the Risks and Opportunities?

Risks

• Regulatory Delays: Additional trial data requirements could postpone approvals.
• Market Competition: Emergence of alternative treatments may suppress sales.
• Pricing Pressure: Payers may restrict reimbursement levels impacting profitability.

Opportunities

• Increased Indication Approval: Success in other inflammatory diseases broadens the revenue base.
• Market Expansion: Countries with rising dermatology burden (e.g., Asia-Pacific) present growth avenues.
• Combination Therapies: Use alongside biologics or corticosteroids offers potential for synergistic effects.

Summary

Tapinarof operates within a growing dermatological market, with initial revenues expected in the hundreds of millions, potentially reaching over a billion dollars yearly with expanded approvals. Its competitive edge hinges on safety, convenience, and novel mechanism. Market penetration depends on regulatory success, pricing, and competitive dynamics.

---

Key Takeaways

• The global dermatology market, valued at $23.4 billion in 2022, provides a substantial backdrop for tapinarof.
• Early sales are projected at $150-200 million in 2023, rising as indications expand.
• Long-term revenues may exceed $1 billion, contingent on approvals and uptake.
• Risks include regulatory hurdles, competitive treatments, and payer restrictions.
• Opportunities exist in broader indications and emerging markets.

---

FAQs

1. What are the main indications for tapinarof?
Initially approved for plaque psoriasis and atopic dermatitis, with ongoing trials for vitiligo and other inflammatory skin diseases.

2. How does tapinarof compare to existing treatments?
It offers a topical, non-immunosuppressive alternative with a favorable safety profile, differentiating it from biologics and corticosteroids.

3. What are the key milestones in tapinarof’s commercial trajectory?
FDA approval in 2022, followed by global launches, and regulatory submissions for additional indications planned through 2024-2026.

4. How significant is market competition?
Considerable, with biologics dominating moderate to severe cases, though tapinarof targets mild to moderate cases and those seeking steroid-sparing options.

5. What factors influence its long-term market success?
Regulatory approvals, indication expansions, competitive positioning, payer reimbursement policies, and market acceptance.

---

Citations

[1] Zion Market Research, "Dermatology Market Size, Share & Industry Analysis," 2022.
[2] DiMasi JA et al., "The Cost of Developing a New Drug," Clinical Pharmacology & Therapeutics, 2016.